Literature DB >> 7081059

Clinical and hemodynamic results of the Fontan operation for tricuspid atresia.

S P Sanders, G B Wright, J F Keane, W I Norwood, A R Castaneda.   

Abstract

Entities:  

Mesh:

Year:  1982        PMID: 7081059     DOI: 10.1016/0002-9149(82)90253-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  7 in total

1.  A model to simulate the haemodynamic effects of right heart pulsatile flow after modified Fontan procedure.

Authors:  S Tamaki; K Kawazoe; T Yagihara; T Abe
Journal:  Br Heart J       Date:  1992-02

2.  Factors associated with stroke following the Fontan procedure.

Authors:  R W Day; R S Boyer; V F Tait; H D Ruttenberg
Journal:  Pediatr Cardiol       Date:  1995 Nov-Dec       Impact factor: 1.655

3.  Functional deterioration of the liver by elevated inferior vena cava pressure: a proposed upper safety limit of pressure for maintaining liver viability in dogs.

Authors:  H Higashiyama; M Yamaguchi; K Kumada; H Sasaki; T Yamaguchi; K Ozawa
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

4.  Computer simulation of circulation in patient with total cavo-pulmonary connection: inter-relationship of cardiac and vascular pressure, flow, resistance and capacitance.

Authors:  A Rydberg; D E Teien; P Krus
Journal:  Med Biol Eng Comput       Date:  1997-11       Impact factor: 2.602

5.  Tricuspid atresia with transposition of the great arteries in adolescents and adults: current state and late complications.

Authors:  C A Warnes; J Somerville
Journal:  Br Heart J       Date:  1987-06

6.  Cerebral infarction complicating Fontan surgery for cyanotic congenital heart disease.

Authors:  K Mathews; J F Bale; E B Clark; W J Marvin; D B Doty
Journal:  Pediatr Cardiol       Date:  1986       Impact factor: 1.655

7.  New extension of the Fontan principle: inferior vena cava-pulmonary artery bridge operation.

Authors:  S Nawa; S Teramoto
Journal:  Thorax       Date:  1988-12       Impact factor: 9.139

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.